ENTITY

Basilea Pharmaceutica Ag (BSLN SW)

50
Analysis
Health CareSwitzerland
Basilea Pharmaceutica AG operates as a biopharmaceutical company. The Company focuses on the research, development, and commercialization of products targeting the medical challenge of resistance and non-response to current treatment options for fungal infections, bacterial infections, and cancer.
more
Refresh
23 Mar 2023 21:16Issuer-paid

Basilea Pharmaceutica - Cresemba expansion continues with Japan launch

Basilea has announced that it has received a development-related milestone payment of CHF5m from its Japanese licensing partner, Asahi Kasei...

Share
17 Feb 2023 20:08Issuer-paid

Basilea Pharmaceutica - Profitability sooner than expected

Basilea reported strong FY22 results following the successful execution of its strategic realignment to focus on anti-infectives. The top-line beat...

Share
25 Jan 2023 18:56Issuer-paid

Basilea Pharmaceutica - Strong execution resulting in operating profitability

On the heels of management’s January upward guidance revision, continued strong execution of Basilea’s outlined strategic plan (February 2022) has...

Share
12 Jan 2023 20:26Issuer-paid

Basilea Pharmaceutica - Revenue upside surprise for 2022

Basilea has announced preliminary, unaudited revenue results for FY22, together with an operational update on its commercial and pipeline assets....

Share
10 Jan 2023 00:48Issuer-paid

Basilea Pharmaceutica - Cresemba milestone payment triggered

Basilea has announced that it has received a sales-related milestone payment of CHF20m from its US licensing partner Astellas Pharma. This was...

Share
x